Design Therapeutics (DSGN) Other Non Operating Income (2020 - 2024)
Design Therapeutics recorded quarterly Other Non Operating Income of $3.2 million in Q3 2024, down 1.32% quarter-over-quarter from $3.2 million in Q2 2024, and up 5.74% year-over-year from $3.0 million in Q4 2023.
Design Therapeutics' Other Non Operating Income history runs 5 years deep, the most recent figure standing at $3.2 million for Q3 2024.
- In Q3 2024, Other Non Operating Income rose 5.74% year-over-year to $3.2 million; the TTM figure through Sep 2024 stood at $13.0 million (up 29.01% YoY), while the FY2023 annual figure was $11.3 million, up 164.36% from the prior year.
- Other Non Operating Income came in at $3.2 million for Q3 2024 at Design Therapeutics, down from $3.2 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $3.3 million in Q1 2024 to a low of -$40000.0 in Q1 2020.
- A 5-year average of $1.4 million and a median of $640000.0 in 2022 frame the typical range for Other Non Operating Income.
- Across the five-year window, Other Non Operating Income tumbled 69.84% in 2021 and jumped 7731.58% in 2022, its largest moves.
- Design Therapeutics' Other Non Operating Income stood at $6000.0 in 2020, then soared by 933.33% to $62000.0 in 2021, then jumped by 3209.68% to $2.1 million in 2022, then soared by 59.8% to $3.3 million in 2023, then slipped by 2.2% to $3.2 million in 2024.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $3.2 million, $3.2 million, and $3.3 million for Q3 2024, Q2 2024, and Q1 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Design Therapeutics | 640.15 Mn | 417.32 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 3.21 Mn |
| Jun 30, 2024 | 3.25 Mn |
| Mar 31, 2024 | 3.30 Mn |
| Dec 31, 2023 | 3.28 Mn |
| Sep 30, 2023 | 3.03 Mn |
| Jun 30, 2023 | 2.66 Mn |
| Mar 31, 2023 | 2.36 Mn |
| Dec 31, 2022 | 2.05 Mn |
| Sep 30, 2022 | 1.49 Mn |
| Jun 30, 2022 | 640,000.00 |
| Mar 31, 2022 | 105,000.00 |
| Dec 31, 2021 | 62,000.00 |
| Sep 30, 2021 | 19,000.00 |
| Jun 30, 2021 | 51,000.00 |
| Mar 31, 2021 | 166,000.00 |
| Dec 31, 2020 | 6,000.00 |
| Sep 30, 2020 | 63,000.00 |
| Jun 30, 2020 | 21,000.00 |
| Mar 31, 2020 | -40,000.00 |